Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2025 | $33.00 | Sell | Goldman |
| 7/28/2025 | $38.00 | Overweight → Neutral | Cantor Fitzgerald |
| 7/23/2025 | $30.00 | Overweight → Equal Weight | Wells Fargo |
| 7/21/2025 | $33.00 | Buy → Hold | TD Cowen |
| 7/16/2025 | $30.00 | Neutral → Underperform | BofA Securities |
| 7/10/2025 | $33.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/2/2025 | $45.00 | Buy → Neutral | UBS |
| 7/2/2025 | $48.00 | Overweight → Neutral | Analyst |
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
8-K - CENTENE CORP (0001071739) (Filer)
8-K - CENTENE CORP (0001071739) (Filer)
SCHEDULE 13G/A - CENTENE CORP (0001071739) (Subject)
Medicare Advantage plans will be available to more than 51 million beneficiaries in 32 states; Prescription Drug Plans will continue to be offered nationwide New in 2026: Wellcare to transition Medicare-Medicaid Plans (MMPs) demonstrations to integrated Dual Eligible Special Needs Plans (D-SNPs) in five states TAMPA, Fla., Oct. 15, 2025 /PRNewswire/ -- Wellcare, a company offering a comprehensive range of Medicare products and the Medicare brand of Centene Corporation (NYSE:CNC), will offer Medicare Advantage (MA) to over 51 million beneficiaries in 32 states and Prescription Drug Plan (PDP) products to more than 8 million members across all 50 states. This includes 51 new counties across ei
Medicare Advantage plans will be available to more than 51 million beneficiaries in 32 states; Prescription Drug Plans will continue to be offered nationwide New in 2026: Wellcare to transition Medicare-Medicaid Plans (MMPs) demonstrations to integrated Dual Eligible Special Needs Plans (D-SNPs) in five states TAMPA, Fla., Oct. 15, 2025 /PRNewswire/ -- Wellcare, a company offering a comprehensive range of Medicare products and the Medicare brand of Centene Corporation (NYSE:CNC), will offer Medicare Advantage (MA) to over 51 million beneficiaries in 32 states and Prescription Drug Plan (PDP) products to more than 8 million members across all 50 states. This includes 51 new counties across ei
WEST ALLIS, Wis., Oct. 6, 2025 /PRNewswire/ -- MHS Health Wisconsin ("MHS Health"), one of Wisconsin's leading health maintenance organizations (HMOs) and a company of Centene Corporation (NYSE:CNC), achieved a 4.5-Star rating from the National Committee for Quality Assurance (NCQA) and ranks among the top 14 Medicaid health plans nationwide. MHS Health is the only Medicaid HMO in Wisconsin to receive this distinction and the highest rating ever received by a Wisconsin Medicaid HMO for more than five years. For more than four decades, MHS Health has been a trusted partner in c
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
Goldman initiated coverage of Centene with a rating of Sell and set a new price target of $33.00
Cantor Fitzgerald downgraded Centene from Overweight to Neutral and set a new price target of $38.00
Wells Fargo downgraded Centene from Overweight to Equal Weight and set a new price target of $30.00
Derrick Duke Appointed Chief Executive Officer After Transition Period Fran Soistman to Retire, Remain on eHealth Board of Directors AUSTIN, Texas, July 29, 2025 /PRNewswire/ -- eHealth, Inc. (NASDAQ:EHTH), a leading private online health insurance marketplace (the "Company"), today announced that the Company's Board of Directors has appointed Derrick Duke as its next Chief Executive Officer. Duke will join eHealth on August 4th 2025, to begin the transition process before officially stepping into the CEO role and joining the Board of Directors on September 18th, 2025. He will succeed Fran Soistman, who, as previously announced, will retire from his role as CEO while continuing to serve on t
Board further strengthened with appointment of Mike McFarland as Director National Veterinary Associates Group ("NVA"), a leading veterinary care organization, today announced it has strengthened its Board with the appointments of Ken Burdick as Executive Chairman and Dr. James "Mike" McFarland as Director. These executives bring substantial healthcare and public company experience ahead of the company's future IPO. Burdick is a seasoned public company executive with more than 40 years of healthcare experience. He currently serves as Executive Chairman at LifeStance Health (NASDAQ:LFST), a leading U.S. provider of outpatient mental healthcare. Since joining LifeStance as Chairman and CEO
ST. LOUIS, Feb. 24, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today the appointment of Kenneth Y. Tanji to the Centene Board of Directors, effective February 20, 2025. Mr. Tanji will serve on the Company's Audit and Compliance Committee. The appointment of Mr. Tanji expands Centene's Board of Directors to 12 members. Mr. Tanji's finance acumen spans more than three decades and includes deep knowledge of capital optimization strategies, strategic acquisitions, JV partnership models and the use of advanced analytics and technologies to scale g
ST. LOUIS, Sept. 29, 2025 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 third quarter financial results at approximately 6:00 a.m. ET on Wednesday, October 29, 2025, and host a conference call at 9:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 0266211 to ex
-- Diluted Loss Per Share of $(0.51); Adjusted Diluted Loss Per Share of $(0.16) -- ST. LOUIS, July 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the second quarter ended June 30, 2025. In summary, the 2025 second quarter results were as follows: Total revenues (in millions) $ 48,742 Premium and service revenues (in millions) $ 42,467 Health benefits ratio 93.0 % SG&A expense ratio 7.1 % Adjusted SG&A expense ratio (1) 7.1 % GAAP diluted loss per share $ (0.51) Adjusted diluted loss per share (1) $ (0.16) Total cash flow provided by operations (in millions) $
CALL MOVED TO 8AM ET ST. LOUIS, July 22, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 second quarter financial results at approximately 6:00 a.m. ET on Friday, July 25, 2025, and host a conference call at 8:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 7878291 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com,
SC 13G - CENTENE CORP (0001071739) (Subject)
SC 13G/A - CENTENE CORP (0001071739) (Subject)
SC 13G/A - CENTENE CORP (0001071739) (Subject)